As shown in Figure 2C, we found that Nfib overexpression rapidly accelerated time to SCLC with a median time to morbidity of 256 days in the Rb/p53/TET-Nfib model vs. 324 days in the Rb/p53 controls (p = 0.04, log-rank test). This evidence concerns the gene NFIB and small cell lung carcinoma.